LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V. (NASDAQ:OFIX) (the Company) today announced
the appointment of Anthony F. Martin, PhD to its Board of Directors,
effective immediately. Dr. Martin has more than 25 years of
international experience in managing life science businesses in both
executive and non-executive roles.
Randy Thurman, Chairman of the Board of Orthofix, commented, "Coupled
with the recent announcement of Kathy Regan and me joining the board,
Dr. Martin's addition marks a new era for Orthofix. In addition to the
revitalized board, Brad Mason, Orthofix's CEO, rejoined the company
earlier this year and has put in place a seasoned and motivated
leadership team, many of whom are new to Orthofix or their roles. In
addition to resolving the financial restatement in a timely manner, we
are focused on reinvigorating both product and clinical development
strategies, establishing leadership in our strategic business units and
creating long-term value for our shareholders."
Dr. Martin has a Doctorate in Immunology from the University of
Manchester Medical School and a first class Honors degree in Applied
Chemistry from the University of Huddersfield. He began his career with
Proctor & Gamble UK before moving to Amersham International,
subsequently GE, in marketing and business development roles. He has
significant experience in fundraising and building medical technology
companies, including in chief executive officer and chairman roles.
Anthony Martin PhD
Dr. Martin has more than 25 years of international experience in
managing life science businesses in both executive and non-executive
roles. He is currently the Non-Executive Chairman of Immunodiagnostics
Systems Holdings plc, Sphere Medical Holding plc, and Phico Therapeutics
Ltd, and a Non-Executive Director of Abcam plc. He gained a doctorate in
Immunology from the University of Manchester Medical School and a first
class honors degree in Applied Chemistry from Huddersfield University.
Dr. Martin has previously served as chief executive officer at a number
of international life sciences and diagnostic businesses including
British Bio-Technology Products ltd, Celsis International plc, AZUR
Environmental, the molecular biology division of Invitrogen Corporation,
and Molecular Probes Inc. He has also previously served as the Chairman
of NeuTec Pharma plc and Molecular Insight Pharmaceuticals Inc. and as a
board member of Prelude Trust plc and Invitrogen Corporation. In
addition, he previously served on the scientific advisory Board of
Agilent Technologies.
The Orthofix board believes that Dr. Martin's extensive experience as an
international operational CEO, combined with his deep knowledge of the
UK institutional shareholder base for medical companies and UK financing
matters, will add significant value to the board as the Company seeks to
grow its UK and European operations and market presence. The board also
believes that his experience serving with both UK and US public
companies will bring added depth and a cross-border perspective with
board governance matters.
About Orthofix:
Orthofix International N.V. is a diversified, global medical device
company focused on developing and delivering innovative orthopedic
solutions that drive value for patients, surgeons, and providers.
Orthofix's products are widely distributed around the world to surgeons
and patients via Orthofix's sales representatives and its subsidiaries,
and via collaborations with other leading orthopedic product companies.
In addition, Orthofix is collaborating on R&D activities with leading
research and clinical organizations such as the Musculoskeletal
Transplant Foundation and Education Foundation and Texas Scottish Rite
Hospital for Children. For more information about Orthofix, please visit www.orthofix.com.
Orthofix International N.V.
Mark Quick, 214-937-2924
Director
of Investor Relations
markquick@orthofix.com
Source: Orthofix International N.V.
News Provided by Acquire Media